Metabolic imaging predicts neoadjuvant therapy response before pancreatic cancer surgery

September 9, 2022

The addition of 18-fluorodeoxyglucose to PET provided significant prognostic benefit in objective assessment of neoadjuvant chemotherapy response among patients with borderline resectable/locally advanced pancreatic cancer.The findings, published in JNCCN — Journal of the National Comprehensive Cancer Network — may help guide decisions on whether to proceed with complex surgery, continue current treatment or consider a chemotherapy switch, researchers noted.Anatomic imaging with CT or MRI poorly predicts response to neoadjuvant therapy among patients with borderlineRead More

Categories: News

Related Articles

Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer

Neoadjuvant modified FOLFIRINOX alone vs. with hypofractionated radiotherapy demonstrated favorable OS among patients with borderline resectable pancreatic cancer, according to results of a phase 2…

Nimotuzumab plus gemcitabine prolongs survival in KRAS wild-type pancreatic cancer

CHICAGO — The addition of nimotuzumab to gemcitabine prolonged OS and PFS among patients with KRAS wild-type locally advanced or metastatic pancreatic cancer, according to…

Dostarlimab shows efficacy as curative-intent treatment in rectal cancer subset

CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced…

Poor sleep increases odds for metabolic dysfunction-associated fatty liver disease

Adults who go to sleep later, snore and nap for more than 30 minutes during the day are more likely to develop metabolic dysfunction-associated fatty…

Exercise may improve chemotherapy efficacy in esophageal cancer

Patients with esophageal cancer who engaged in prehabilitation exercise demonstrated improved responses to neoadjuvant chemotherapy than those who did not, according to a study published…